drugset / Trial / NCT00726505

Renal Mechanism of Action/Splay vs. TmG

NCT00726505

Phase 1 Terminated 1 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus

Timeline

Start
2009-06
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 5 mg Oral
Comparator Dapagliflozin Small molecule 20 mg Oral

Indications